You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Since the commercial launch of its technology last year, the firm has been validating it in studies with academic groups and pharmaceutical companies.
An integrated proteogenomic analysis led to previously unappreciated treatment targets or prognostic markers in craniopharyngioma, high-grade glioma, and other tumor types.
Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.
The New York Times had geneticists sequence SARS-CoV-2 samples from two journalists who contracted the virus while covering the White House.
In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.
By combining genome sequence data with phylogenetics and other clues, two teams looked at the SARS-CoV-2 introductions that sparked outbreaks in North America and Europe.
In PNAS this week: genetic diversity of SARS-CoV-2 indicates neutral evolution, portable RT-LAMP method to detect SARS-CoV-2, and more.
Researchers have been using Nextstrain, which includes data for thousands of SARS-CoV-2 genomes, to study how the virus accrues mutations over time.
The researchers applied their approach to study the heterogeneity of immune cells and adapted a visualization tool to analyze the data.
Bloomberg writes that Fred Hutchinson Cancer Research Center's Trevor Bedford and his colleagues continue to use viral genomics to track SARS-CoV-2.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.